Phase II trial of bisantrene for advanced hypernephroma.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000873:Anthracenes / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*
D000873:Anthracenes; D000970:Antineoplastic Agents; C031404:bisantrene